The monthly volume of human papillomavirus (HPV) vaccine doses administered have returned to the level observed prior to the COVID-19 pandemic among children in an integrated health care system in California, but HPV vaccine coverage remains lower compared with prepandemic levels.
The percentage of children with up-to-date human papillomavirus (HPV) vaccine coverage remains lower compared with pre–COVID-19 pandemic levels, according to study findings published in Vaccine.
Historically, uptake of the HPV vaccine has been lower compared with other vaccines among children and adolescents. Researchers note that a steady increasing trend in HPV vaccine coverage (% vaccinated) in adolescents has been observed nationally since 2006, but the substantial disruptions to preventive care services caused by the COVID-19 pandemic have been shown to impact this progress.
“Little is known about whether the HPV vaccine administration pattern persisted throughout the pandemic and how HPV vaccine coverage is affected,” said the study authors. “Such data will be critical to inform strategies to reduce potential disparities.”
They conducted an analysis of data from electronic medical records at Kaiser Permanente Southern California (KPSC), a large integrated health care delivery system serving over 4.7 million members, to assess monthly volume of HPV vaccine doses administered among children aged 9 to 12.9 years, and up-to-date coverage by age 13 between March 1, 2019, to September 30, 2021.
The study also examined the impact of the COVID-19 pandemic on HPV vaccination by race/ethnicity and neighborhood deprivation index (NDI). Modified Poisson models were used to evaluate the interactions between race/ethnicity, NDI, and the pandemic periods on HPV vaccine coverage.
“HPV vaccination is offered at KPSC without cost and can be obtained at primary care and pediatric clinics, nurse clinics, urgent care, or emergency rooms,” explained researchers.
From March to April 2020, there was a large decline in administered HPV vaccine doses, which returned to the 2019 level by May 2020. Another decline was observed in January 2021, followed by a rapid reversal as of February 2021. Similar patterns were observed across sex and race/ethnicity.
Findings further indicated that the average up-to-date coverage in May 2021 to September 2021 (54.8%) remained lower than the prepandemic level (58.5%). The associations between race/ethnicity, NDI, and HPV vaccine coverage did not vary due to the pandemic.
As HPV vaccine uptake patterns during the pandemic may have varied by state and health care systems, researchers said results may not generalize to those outside of California, who are uninsured, or not in an integrated health care system.
“System efforts for promoting childhood and adolescent vaccination during a pandemic are likely necessary to ensure adequate vaccination rates. Enhanced efforts are needed to bring back the HPV vaccination coverage level in children,” they concluded.
Reference
Chao CR, Xu L, Cannizzaro N, et al. Trends in HPV vaccine administration and HPV vaccine coverage in children by race/ethnicity and socioeconomic status during the COVID-19 pandemic in an integrated health care system in California. Vaccine. 2022;40(46):6575-6580. doi:10.1016/j.vaccine.2022.09.073
5 Things Everyone Should Know for National Immunization Awareness Month
August 1st 2025National Immunization Awareness Month highlights the importance of lifelong vaccination to prevent diseases, a practice that has averted millions of deaths, proven to be a cost-effective public health strategy, and offers crucial protection even to individuals who are immunocompromised.
Read More
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More